Pulmonology Department, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), San Carlos Clinical Hospital, Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
BMC Health Serv Res. 2023 Jan 30;23(1):98. doi: 10.1186/s12913-023-09094-3.
Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study's aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts' recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation.
A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative.
COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals.
The study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts' recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.
患有α-1 抗胰蛋白酶缺乏症(AATD)的患者通常被归类为罕见病,他们受到了 COVID-19 带来的医疗保健管理变化的影响。本研究旨在确定 COVID-19 大流行对西班牙 AATD 患者护理带来的变化,并提出专家建议,旨在确保 AATD 患者在疫情后得到人性化和高质量的护理。
采用定性描述性个案研究和整体单案例设计,对 AATD 临床管理专家进行焦点小组讨论,包括与西班牙卫生系统有联系的 15 名卫生专业人员(12 名肺病专家和 2 名来自西班牙 11 家不同医院的医院药剂师)和 1 名患者代表。
COVID-19 对西班牙 AATD 临床患者管理的许多方面都产生了重大影响,包括诊断、治疗和随访阶段。专家们得出结论,需要加强初级保健和医院保健之间的协调,并改善所有参与医疗保健系统的组织和行为者之间的协调流程。关于远程医疗和远程护理,专家们认为有必要推广这种方法,并制定协议和培训计划。专家们建议发展个性化和精准医学,以及患者参与决策,促进自我护理和患者自主,以优化他们的医疗保健并提高他们的生活质量。专家们还提出了从家中监测和治疗 AATD 患者的可能性。该研究的另一个结果是建议确保定期有足够数量的健康个体进行血浆捐赠。
本研究通过强调 COVID-19 大流行背景下卫生专业人员面临的挑战和 AATD 患者管理的变化,增进了人们对这一领域的认识。它还提出了专家建议,旨在确保 AATD 患者在疫情后得到人性化和高质量的护理。这项工作可以作为医生日常临床实践中治疗 AATD 患者的参考研究,也可以为疫情后需要进行的变革提供指导。